---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-261704"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2023-10-24T23:59:59+00:00"
generated_at: "2026-06-09T14:02:53.439640+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# EMA grants PRIME designation for Annexon's ANX007 in geographic atrophy

## Summary
- PRIME designation based on Phase 2 ARCHER trial showing preservation of visual function.
- ANX007 is the first therapeutic candidate for GA to receive EMA PRIME designation.
- Company engaging with U.S. and EU regulators to design global Phase 3 program.
- Designation provides enhanced EMA support to expedite development and review.

## SEC filing metadata
- accession: 0001193125-23-261704
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2023-10-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312523261704/0001193125-23-261704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312523261704/d482545d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-261704
- JSON: https://secwatch.observer/filing/0001193125-23-261704.json
- Plain text: https://secwatch.observer/filing/0001193125-23-261704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.